POZEN

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, POZEN sits in the top decile of US sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count).

24 total trials none currently recruiting 23 completed top decile by trial count

POZEN: 24 sponsored US clinical trials, none currently recruiting.

POZEN sponsors 24 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 23 completed. 12 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gastric Ulcer, with 1 trials.

Top-decile sponsor footprint

POZEN ranks in the top decile of sponsors by registered trial count (#648 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 79/100

23 of 24 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

24 total, page 1 of 1

COMPLETED Phase 1

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

NCT01557335

COMPLETED Phase 3

Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers

NCT00995410

COMPLETED Phase 3

A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

NCT00961350

COMPLETED Phase 3

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

NCT00960869

COMPLETED Phase 1

A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels

NCT00749385

COMPLETED Phase 1

Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib

NCT00729495

COMPLETED Phase 1

Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations

NCT00692055

COMPLETED Phase 1

Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib

NCT00700687

COMPLETED Phase 1

Study Evaluating the Effect of Food on the Bioavailability of PN400 Components

NCT00676442

COMPLETED Phase 3

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

NCT00664560

COMPLETED Phase 3

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

NCT00665431

COMPLETED Phase 1

Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations

NCT00665743

COMPLETED Phase 3

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen

NCT00527787

TERMINATED Phase 3

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec

NCT00594854

COMPLETED Phase 3

A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)

NCT00527904

COMPLETED Phase 1

A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin

NCT00441519

COMPLETED Phase 1

An Open-Label, Randomized, Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy Volunteers

NCT00442208

COMPLETED Phase 1

To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin

NCT00442052

COMPLETED Phase 3

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

NCT00367211

COMPLETED Phase 2

Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.

NCT00293657

COMPLETED Phase 2

Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After Bunionectomy

NCT00293631

COMPLETED Phase 3

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches

NCT00433732

COMPLETED Phase 3

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches

NCT00434083

COMPLETED Phase 3

The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months

NCT00442221

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 2
Phase 3 12

How the POZEN archive is shaped

24 indexed studies, none listed as recruiting (0% open); 23 completed (96%).

Phase mix: 12 late (III/IV) vs 12 early (I/II) (balanced across stages).

Top condition: Gastric Ulcer (1 trial), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

POZEN: archived-pipeline peers nationwide

Peers matched on 24 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

POZEN sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015202530 0%10%20%30% Total trials Recruiting share POZENAcrotech BiopharmaAgenusAkebia TherapeuticsBlueprint Medicines Corporation10xBio22nd Century Group23andMe3-C Institute for Social Development
POZEN sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

POZEN sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 24 archived trials

Sponsors with similar archive density (± trial count)

What to do with this POZEN page

24 registered trials is a research-attention snapshot, not an endorsement of POZEN or any single study.

  • None of POZEN's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Gastric Ulcer is the condition POZEN studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gastric Ulcer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

POZEN pipeline card: 24 registered trials from official public datasets.Report a data error.